SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000921895-15-002763
Filing Date
2015-12-11
Accepted
2015-12-10 19:50:49
Documents
3

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D sc13d07422010_12102015.htm SC 13D 251476
2 EX. 99.1 - LETTER AGREEMENT ex991to13d07422010_12102015.pdf SC 13D 132219
3 JOINT FILING AGREEMENT ex992to13d07422010_12102015.htm EX-99.2 33891
  Complete submission text file 0000921895-15-002763.txt   469364
Mailing Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Subject) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: WA | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-48459 | Film No.: 151281948
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1 SANSOME ST 30TH FL SAN FRANCISCO CA 94104
Business Address 1 SANSOME ST 30TH FL SAN FRANCISCO CA 94104 3125066500
BIOTECHNOLOGY VALUE FUND L P (Filed by) CIK: 0000918923 (see all company filings)

IRS No.: 363924731 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D
SIC: 6282 Investment Advice